Iradimed Sees Q4 Revenue Up to $26.5M, With 3870 Revenue Up More Than 50% Sequentially

Iradimed expects fourth-quarter 2026 revenue of $25 million to $26.5 million, with revenue from its 3870 MR IV pump projected to grow more than 50% from the previous quarter as production ramps.

The company produced more than 400 3870 systems in the third quarter. Management is pacing the production ramp to avoid quality problems.

Third-quarter gross margin rose to 76% from the previous quarter. Iradimed expects further gains in the fourth quarter as volume rises, moving toward its historical range of 77% to 78%. The company also said international sales can pressure margins.

Founder, Chairman, CEO and President Roger Susi said the pump launch was “showing itself to be everything we had hoped for and more.”